FILE 'HOME' ENTERED AT 09:00:30 ON 08 DEC 2008

=> FIL REGISTRY
FILE 'REGISTRY' ENTERED AT 09:00:39 ON 08 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1
DICTIONARY FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
[RK][ARNQGHILKMFPSTWVY]C[AGS][TAGS][HILMFPTVWY][HILMFPTVWY][AGSHILMFPTVWYNQ][ARNQGHI
LKMFPSTWVY][RKHILMFPTVWYNQ][HILMFPTVWY][HILMFPTVWY][HILMFPTVWY][SHILMFPTVWY][AGS][AG
SHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP
L1 0 [RK][ARNQGHILKMFPSTWVY]C[AGS][TAGS][HILMFPTVWY][HILMFPTVWY][AGSH
ILMFPTVWYNQ][ARNQGHILKMFPSTWVY][RKHILMFPTVWYNQ][HILMFPTVWY][HILM
FPTVWY][HILMFPTVWY][SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTV
WYNQ]C[AGSHILMFPTVWY]/SQSP

=>
[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV
][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVW
Y][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP
L2 4577 [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPT
VWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFP
TVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGS
HILMFPTVWY]/SQSP

=> l2 and sql<=29
6887764 SQL<=29
L3 32 L2 AND SQL<=29

=>
^.{1-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKM
FPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHI
LMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY].{1-5}/SQSP
L4 37 ^.{1-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGS
HILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ](

```
                [HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYN
                Q]C[AGSHILMFPTVWY].{1-5}/SQSP

=>
^.{2-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKM
FPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHI
LMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY].{1-5}/SQSP
L5          35 ^.{2-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGS
               HILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ](
               [HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYN
               Q]C[AGSHILMFPTVWY].{1-5}/SQSP

=>
[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV
][PRQ][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTV
WYNQ]C[AGSHILMFPTVWY]/SQSP
L6        1428 [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPT
               VWYANRQGHILKMFPSTWYV][PRQ][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHIL
               MFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQ
               SP

=>
[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV
][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVW
Y][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY][RA]/SQSP
L7         277 [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPT
               VWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFP
               TVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGS
               HILMFPTVWY][RA]/SQSP

=>
[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV
][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVW
Y][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]Q/SQSP
L8         251 [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPT
               VWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFP
               TVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGS
               HILMFPTVWY]Q/SQSP

=>
[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV
][ANRQGHILKMFPSTWYV][NQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFP
TVWYNQ]C[AGSHILMFPTVWY]/SQSP
L9        1447 [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPT
               VWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][NQ]([HILMFPTVWY]){3}[SH
               ILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/
               SQSP

=> l2 and sql=<44
      8728334 SQL=<44
L10         35 L2 AND SQL=<44

=> l10 and l6
L11         12 L10 AND L6

=> l10 and l7
```

```
L12          11 L10 AND L7

=> l10 and l8
L13          19 L10 AND L8

=> l10 and l9
L14           5 L10 AND L9

=> l11 or l12 or l13 or l14
L15          33 L11 OR L12 OR L13 OR L14

=> FIL CAPLUS
FILE 'CAPLUS' ENTERED AT 09:08:37 ON 08 DEC 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)
```



```
FILE COVERS 1907 - 8 Dec 2008  VOL 149 ISS 24
FILE LAST UPDATED: 7 Dec 2008  (20081207/ED)

Caplus now includes complete International Patent Classification (IPC)
reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply.
They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> l15
L16          26 L15

=> l16 and pd<=20030814
     23849345 PD<=20030814
                (PD<=20030814)
L17          17 L16 AND PD<=20030814

=> l16 and prd<=20030814
      4147234 PRD<=20030814
                (PRD<=20030814)
L18          15 L16 AND PRD<=20030814

=> l16 and ( pd<=20020814 or prd<=20020814)
     22810451 PD<=20020814
                (PD<=20020814)
      3855329 PRD<=20020814
```

(PRD<=20020814)
L19 20 L16 AND (PD<=20020814 OR PRD<=20020814)

=> d l19 1-20 ibib hitseq

L19 ANSWER 1 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:20444 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 140:110119
TITLE: Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases
INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallon, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004002424	A2	20040108	WO 2003-US20495		20030630 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2490411	A1	20040108	CA 2003-2490411		20030630 <--
AU 2003256336	A1	20040119	AU 2003-256336		20030630 <--
BR 2003012276	A	20050426	BR 2003-12276		20030630 <--
US 20050191301	A1	20050901	US 2003-609783		20030630
US 7241733	B2	20070710			
EP 1575499	A2	20050921	EP 2003-762210		20030630 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005536992	T	20051208	JP 2004-518080		20030630 <--
CN 1735433	A	20060215	CN 2003-820110		20030630 <--
IN 2004KN01988	A	20060707	IN 2004-KN1988		20041224 <--
MX 2005PA00202	A	20050930	MX 2005-PA202		20050103 <--
PRIORITY APPLN. INFO.:			US 2002-392431P	P	20020628 <--
			US 2002-412144P	P	20020919
			WO 2003-US20495	W	20030630

IT **645406-06-0**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, mimetibody comprising; mammalian EPO mimetic CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)

RN 645406-06-0 CAPLUS

CN L-Alanine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFA 25

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 10 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:210198 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 132:218021
TITLE: Cloning and cDNA and deduced amino acid sequences of 31 human secreted proteins
INVENTOR(S): Ruben, Steven M.; Rosen, Craig A.; Duan, Roxanne D.; Shi, Yanggu; Lafleur, David W.; Young, Paul E.; Ni, Jian; Komatsoulis, George; Endress, Gregory A.; Soppet, Daniel R.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; et al.
SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017222	A1	20000330	WO 1999-US22012	19990922 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2344100	A1	20000330	CA 1999-2344100	19990922 <--
AU 9959288	A	20000410	AU 1999-59288	19990922 <--
EP 1115735	A1	20010718	EP 1999-946997	19990922 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002526059	T	20020820	JP 2000-574130	19990922 <--
US 20020076705	A1	20020620	US 2001-820893	20010330 <--
US 20040048294	A1	20040311	US 2003-607565	20030627 <--

PRIORITY APPLN. INFO.:

US 1998-101546P	P	19980923 <--
US 1998-102895P	P	19981002 <--
WO 1999-US22012	W	19990922 <--
US 2000-531119	B1	20000320 <--
US 2001-820893	B1	20010330 <--

IT **261164-15-2**
RL: PRP (Properties)
(unclaimed sequence; cloning and cDNA and deduced amino acid sequences of 31 human secreted proteins)
RN 261164-15-2 CAPLUS
CN L-Tryptophan, L-threonyl-L-cysteinylglycylglycyl-L-seryl-L-valyl-L-leucyl-L-alanyl-L-prolyl-L-arginyl-L-tryptophyl-L-valyl-L-valyl-L-threonyl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-methionyl-L-histidyl-L-seryl-L-phenylalanyl-L-arginyl-L-leucyl-L-alanyl-L-arginyl-L-leucyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)

SEQ 1 TCGGSVLAPR WVVTAAHCMH SFRLARLSSW

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 1-C



PAGE 2-A



PAGE 2-B



PAGE 2-C



PAGE 2-D



REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 11 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:601254 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:306552
ORIGINAL REFERENCE NO.: 127:59951a
TITLE: Interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes
AUTHOR(S): Polikandritou Lambros, Maria; Sheu, Eric; Lin, J. S.; Pereira, H. Anne
CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
SOURCE: Biochimica et Biophysica Acta, Biomembranes (**1997**), 1329(2), 285-290
CODEN: BBBMBS; ISSN: 0005-2736
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **151679-59-3P**

RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 12 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:408609 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:148252
ORIGINAL REFERENCE NO.: 127:28629a
TITLE: A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats
AUTHOR(S): Brackett, Daniel J.; Lerner, Megan R.; Lacquement, Melissa A.; He, Rong; Pereira, H. Anne
CORPORATE SOURCE: Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73190, USA
SOURCE: Infection and Immunity (**1997**), 65(7), 2803-2811
CODEN: INFIBR; ISSN: 0019-9567
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal

LANGUAGE: English

IT **151679-59-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(synthetic lipopolysaccharide-binding peptide based on neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 13 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:344807 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:13456
ORIGINAL REFERENCE NO.: 127:2623a,2626a
TITLE: Method and composition for the treatment of septic shock
INVENTOR(S): Pereira, Heloise A.
PATENT ASSIGNEE(S): University of Oklahoma, USA
SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,607,916.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:			US 1989-375739 B2	19890705 <--
			US 1990-543151 B2	19900625 <--
			US 1992-855417 A1	19920319 <--
			US 1992-969931 A2	19921030 <--
			US 1994-235399 A2	19940429 <--
			US 1992-939931 A2	19921030 <--
			US 1995-482328 A1	19950607 <--
			US 1997-840519 A1	19970421 <--

IT **151679-59-3**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(method and composition for the treatment of septic shock)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 14 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1997:204303 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER:	126:207540
ORIGINAL REFERENCE NO.:	126:40001a
TITLE:	Method and composition using lipopolysaccharide-binding peptide derived from CAP37 protein for the treatment of septic shock
INVENTOR(S):	Pereira, Heloise A.; Brackett, Daniel J.; Lerner, Megan R.
PATENT ASSIGNEE(S):	Board of Regents of the University of Oklahoma, USA
SOURCE:	U.S., 19 pp., Cont.-in-part of U.S.5,458,874. CODEN: USXXAM
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	5
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
US 5650392	A	19970722	US 1995-455485	19950531 <--
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:			US 1989-375739 B2	19890705 <--
			US 1990-543151 B2	19900625 <--
			US 1992-855417 A1	19920319 <--
			US 1992-969931 A2	19921030 <--
			US 1992-939931 A2	19921030 <--
			US 1994-235399 A3	19940429 <--
			US 1995-482328 A1	19950607 <--
			US 1997-840519 A1	19970421 <--

IT **151679-59-3**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(lipopolysaccharide-binding peptide derived from CAP37 protein for the treatment of septic shock)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 15 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:8914 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 126:56203
ORIGINAL REFERENCE NO.: 126:10991a,10994a
TITLE: Isolation and characterization of a peptide from funnel web spider (Agelenopsis aperta) venom
INVENTOR(S): Yomo, Yasushi; Kuwata, Manabu; Teramoto, Tetsuyuki; Niitome, Tetsuhiro; Sawada, Kohei; Nishizawa, Yukio
PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

JP 08253499 A 19961001 JP 1994-328130 19941228 <--
PRIORITY APPLN. INFO.: JP 1994-328130 19941228 <--
IT **184786-10-5P**
RL: PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; isolation and characterization of a peptide from funnel web spider (Agelenopsis aperta) venom)
RN 184786-10-5 CAPLUS
CN Protein (Agelenopsis aperta venom agatoxin-like) (9CI) (CA INDEX NAME)

NTE multichain

SEQ 1 IVGGKTAKFG DYPWMVSIQQ KNKKGTFDHI CGGAIINVNW ILTAAHCFDQ
51 PIVKSDYRAY VGLRSILHTK ENTVQRLELS KIVLHPGYKP KKDPDDIALI
101 KVAKPIVIGN YANGICVPKG VTNPEGNATV IGWGKISSGG KQVNTLQEVT
151 IPIIPWKKCK EIYGDEFSEF EYSQITPYMI CAGAEGKDSC QADSGGPLFQ
201 IDANGVATLI GTVANGADCG YKHYPGVYMK VSSYTNWMSK NMV

1 VEVATVKNCG KKLLATPR

L19 ANSWER 16 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:137923 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 124:315067
ORIGINAL REFERENCE NO.: 124:58442h,58443a
TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
INVENTOR(S): Pereira, Heloise A.; Spitznagel, John K.
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 543,151, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9348089	A	19931021	AU 1993-48089	19930319 <--
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5650392	A	19970722	US 1995-455485	19950531 <--
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:			US 1989-375739 B2	19890705 <--
			US 1990-543151 B2	19900625 <--
			US 1992-855417 A1	19920319 <--
			US 1992-939931 A2	19921030 <--

US 1992-969931	A2	19921030 <--
WO 1993-US2580	A	19930319 <--
US 1994-235399	A3	19940429 <--
US 1995-482328	A1	19950607 <--
US 1997-840519	A1	19970421 <--

IT **151679-59-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chemotactic/antibiotic/lipopolysaccharide-binding peptide fragments of CAP37 for treating wounds, tumors, and infections)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 17 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:32761 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 124:114140
ORIGINAL REFERENCE NO.: 124:21195a,21198a
TITLE: A cationic antimicrobial peptide enhances the infectivity of Coxiella burnetii
AUTHOR(S): Aragon, A. S.; Pereira, H. A.; Baca, O. G.
CORPORATE SOURCE: Biology Department, University of New Mexico, Albuquerque, NM, 8713-1091, USA
SOURCE: Acta Virologica (English Edition) (**1995**), 39(4), 223-6
CODEN: AVIRA2; ISSN: 0001-723X
PUBLISHER: Slovak Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **151679-59-3**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study)
(CAP3720-44 (a synthetic peptide based on the 37-Kd human neutrophil

granule-associated cationic antimicrobial protein, CAP37) enhances the infectivity of Coxiella burnetii)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 18 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:17399 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 124:84820

ORIGINAL REFERENCE NO.: 124:15949a,15952a

TITLE: Sperm immobilizing activity of a synthetic bioactive peptide 20-44 of 37-kDa cationic antimicrobial protein (CAP37) of human neutrophils

AUTHOR(S): D'Cruz, Osmond J.; Pereira, H. Anne; Haas, Gilbert G. Jr.

CORPORATE SOURCE: Health Sciences Center, University Oklahoma, Oklahoma City, OK, 73190, USA

SOURCE: Journal of Andrology (**1995**), 16(5), 432-40
CODEN: JOAND3; ISSN: 0196-3635

PUBLISHER: American Society of Andrology

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **151679-59-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(sperm immobilization by peptide 20-44 fragment of CAP37 of human neutrophils)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.







PAGE 2-B



PAGE 2-C



L19 ANSWER 19 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:563 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 120:563
ORIGINAL REFERENCE NO.: 120:135a,138a
TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
INVENTOR(S): Pereira, Heloise Anne; Spitznagel, John K.
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--

W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5484885	A	19960116	US 1992-855417		19920319 <--
AU 9348089	A	19931021	AU 1993-48089		19930319 <--
PRIORITY APPLN. INFO.:			US 1992-855417	A	19920319 <--
			US 1989-375739	B2	19890705 <--
			US 1990-543151	B2	19900625 <--
			WO 1993-US2580	A	19930319 <--

IT **151705-32-7 151769-18-5 152699-65-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of)

RN 151705-32-7 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyl-L-glutaminyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQQRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.







PAGE 2-A



PAGE 2-B



RN 151769-18-5 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 152699-65-5 CAPLUS

CN L-Glutamine, L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 FCGGALIHAR FVMTAASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







IT **151679-59-3**
RL: BIOL (Biological study)
(of chemotactic protein, of neutrophil, bactericidal and lipopolysaccharide-binding activity of)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 20 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 119:115274
ORIGINAL REFERENCE NO.: 119:20733a,20736a
TITLE: Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel, John K.
CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (**1993**), 90(10), 4733-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **149315-20-8** **149383-15-3** **149383-16-4** **149383-22-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)
RN 149315-20-8 CAPLUS
CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26→42)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

RN 149383-16-4 CAPLUS
CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 LRGGHFCGAT LIAPNFVMSA AHCVA

Absolute stereochemistry.





PAGE 2-B



PAGE 2-C



PAGE 3-A



PAGE 3-B

RN 149383-22-2 CAPLUS
CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3→19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> l11
L20 3 L11

=> l12
L21 3 L12

=> l13
L22 23 L13

=> l14
L23 3 L14

=> l19 and l20
L24 2 L19 AND L20

=> l19 and l21
L25 2 L19 AND L21

```
=> l19 and l22
L26         17 L19 AND L22

=>

=>

=> l19 and l23
L27          2 L19 AND L23

=> l24 or l25 or l27
L28          4 L24 OR L25 OR L27

=> d ibib l24 1-2

L24  ANSWER 1 OF 2  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2000:210198  CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER:          132:218021
TITLE:                    Cloning and cDNA and deduced amino acid sequences of
                          31 human secreted proteins
INVENTOR(S):              Ruben, Steven M.; Rosen, Craig A.; Duan, Roxanne D.;
                          Shi, Yanggu; Lafleur, David W.; Young, Paul E.; Ni,
                          Jian; Komatsoulis, George; Endress, Gregory A.;
                          Soppet, Daniel R.
PATENT ASSIGNEE(S):       Human Genome Sciences, Inc., USA; et al.
SOURCE:                   PCT Int. Appl., 416 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   1
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.         DATE
     ---------------      ----   --------    --------------------    --------
     WO 2000017222         A1    20000330    WO 1999-US22012         19990922 <--
         W:  AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ,
             DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS,
             JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK,
             MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ,
             TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE,
             DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF,
             CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2344100            A1    20000330    CA 1999-2344100         19990922 <--
     AU 9959288            A     20000410    AU 1999-59288           19990922 <--
     EP 1115735            A1    20010718    EP 1999-946997          19990922 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO
     JP 2002526059         T     20020820    JP 2000-574130          19990922 <--
     US 20020076705        A1    20020620    US 2001-820893          20010330 <--
     US 20040048294        A1    20040311    US 2003-607565          20030627 <--
PRIORITY APPLN. INFO.:                       US 1998-101546P     P   19980923 <--
                                             US 1998-102895P     P   19981002 <--
                                             WO 1999-US22012     W   19990922 <--
                                             US 2000-531119      B1  20000320 <--
                                             US 2001-820893      B1  20010330 <--
```

REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 119:115274
ORIGINAL REFERENCE NO.: 119:20733a,20736a
TITLE: Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel, John K.
CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (**1993**), 90(10), 4733-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English

=> d ibib l24 1-2 hitseq

L24 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:210198 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 132:218021
TITLE: Cloning and cDNA and deduced amino acid sequences of 31 human secreted proteins
INVENTOR(S): Ruben, Steven M.; Rosen, Craig A.; Duan, Roxanne D.; Shi, Yanggu; Lafleur, David W.; Young, Paul E.; Ni, Jian; Komatsoulis, George; Endress, Gregory A.; Soppet, Daniel R.
PATENT ASSIGNEE(S): Human Genome Sciences, Inc., USA; et al.
SOURCE: PCT Int. Appl., 416 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000017222	A1	20000330	WO 1999-US22012	19990922 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2344100	A1	20000330	CA 1999-2344100	19990922 <--
AU 9959288	A	20000410	AU 1999-59288	19990922 <--
EP 1115735	A1	20010718	EP 1999-946997	19990922 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				

JP 2002526059	T	20020820	JP 2000-574130		19990922 <--
US 20020076705	A1	20020620	US 2001-820893		20010330 <--
US 20040048294	A1	20040311	US 2003-607565		20030627 <--
PRIORITY APPLN. INFO.:			US 1998-101546P	P	19980923 <--
			US 1998-102895P	P	19981002 <--
			WO 1999-US22012	W	19990922 <--
			US 2000-531119	B1	20000320 <--
			US 2001-820893	B1	20010330 <--

IT **261164-15-2**
RL: PRP (Properties)
(unclaimed sequence; cloning and cDNA and deduced amino acid sequences of 31 human secreted proteins)

RN 261164-15-2 CAPLUS

CN L-Tryptophan, L-threonyl-L-cysteinylglycylglycyl-L-seryl-L-valyl-L-leucyl-L-alanyl-L-prolyl-L-arginyl-L-tryptophyl-L-valyl-L-valyl-L-threonyl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-methionyl-L-histidyl-L-seryl-L-phenylalanyl-L-arginyl-L-leucyl-L-alanyl-L-arginyl-L-leucyl-L-seryl-L-seryl- (9CI) (CA INDEX NAME)

SEQ 1 TCGGSVLAPR WVVTAAHCMH SFRLARLSSW

Absolute stereochemistry.









PAGE 2-A



PAGE 2-B



PAGE 2-C





REFERENCE COUNT: 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L24 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 119:115274
ORIGINAL REFERENCE NO.: 119:20733a,20736a
TITLE: Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel, John K.
CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (**1993**), 90(10), 4733-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **149315-20-8** **149383-15-3** **149383-16-4** **149383-22-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)
RN 149315-20-8 CAPLUS
CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26→42)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

RN 149383-16-4 CAPLUS

CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 LRGGHFCGAT LIAPNFVMSA AHCVA

Absolute stereochemistry.





PAGE 2-C



PAGE 3-A



PAGE 3-B

RN 149383-22-2 CAPLUS

CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3→19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d ibib l25 1-2 hitseq

L25 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:20444 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 140:110119
TITLE: Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases
INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallon, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 123 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE
WO 2004002424	A2	20040108	WO 2003-US20495		20030630 <--
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW					
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG					
CA 2490411	A1	20040108	CA 2003-2490411		20030630 <--
AU 2003256336	A1	20040119	AU 2003-256336		20030630 <--
BR 2003012276	A	20050426	BR 2003-12276		20030630 <--
US 20050191301	A1	20050901	US 2003-609783		20030630
US 7241733	B2	20070710			
EP 1575499	A2	20050921	EP 2003-762210		20030630 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK					
JP 2005536992	T	20051208	JP 2004-518080		20030630 <--
CN 1735433	A	20060215	CN 2003-820110		20030630 <--
IN 2004KN01988	A	20060707	IN 2004-KN1988		20041224 <--
MX 2005PA00202	A	20050930	MX 2005-PA202		20050103 <--
PRIORITY APPLN. INFO.:			US 2002-392431P	P	20020628 <--
			US 2002-412144P	P	20020919
			WO 2003-US20495	W	20030630

IT **645406-06-0**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL

(Biological study); USES (Uses)
(amino acid sequence, mimetibody comprising; mammalian EPO mimetic CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)

RN 645406-06-0 CAPLUS

CN L-Alanine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFA

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



PAGE 2-C



L25 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>

DOCUMENT NUMBER: 119:115274

ORIGINAL REFERENCE NO.: 119:20733a,20736a

TITLE: Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes

AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel, John K.

CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA

SOURCE: Proceedings of the National Academy of Sciences of the United States of America (**1993**), 90(10), 4733-7
CODEN: PNASA6; ISSN: 0027-8424

DOCUMENT TYPE: Journal

LANGUAGE: English

IT **149315-20-8** **149383-15-3** **149383-16-4** **149383-22-2**

RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)

RN 149315-20-8 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26→42)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

RN 149383-16-4 CAPLUS

CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 LRGGHFCGAT LIAPNFVMSA AHCVA



Absolute stereochemistry.









PAGE 3-A



PAGE 3-B

RN 149383-22-2 CAPLUS
CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3→19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d ibib l27 1-2 hitseq

L27 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:8914 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 126:56203
ORIGINAL REFERENCE NO.: 126:10991a,10994a
TITLE: Isolation and characterization of a peptide from funnel web spider (Agelenopsis aperta) venom
INVENTOR(S): Yomo, Yasushi; Kuwata, Manabu; Teramoto, Tetsuyuki; Niitome, Tetsuhiro; Sawada, Kohei; Nishizawa, Yukio
PATENT ASSIGNEE(S): Eisai Co Ltd, Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 7 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 08253499	A	19961001	JP 1994-328130	19941228 <--
PRIORITY APPLN. INFO.:			JP 1994-328130	19941228 <--

IT **184786-10-5P**
RL: PRP (Properties); PUR (Purification or recovery); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(amino acid sequence; isolation and characterization of a peptide from funnel web spider (Agelenopsis aperta) venom)
RN 184786-10-5 CAPLUS
CN Protein (Agelenopsis aperta venom agatoxin-like) (9CI) (CA INDEX NAME)

NTE multichain

SEQ
```
  1 IVGGKTAKFG DYPWMVSIQQ KNKKGTFDHI CGGAIINVNW ILTAAHCFDQ
 51 PIVKSDYRAY VGLRSILHTK ENTVQRLELS KIVLHPGYKP KKDPDDIALI
101 KVAKPIVIGN YANGICVPKG VTNPEGNATV IGWGKISSGG KQVNTLQEVT
151 IPIIPWKKCK EIYGDEFSEF EYSQITPYMI CAGAEGKDSC QADSGGPLFQ
201 IDANGVATLI GTVANGADCG YKHYPGVYMK VSSYTNWMSK NMV

  1 VEVATVKNCG KKLLATPR
```

L27 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER:	119:115274
ORIGINAL REFERENCE NO.:	119:20733a,20736a
TITLE:	Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes
AUTHOR(S):	Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel, John K.
CORPORATE SOURCE:	Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE:	Proceedings of the National Academy of Sciences of the United States of America (**1993**), 90(10), 4733-7 CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE:	Journal
LANGUAGE:	English

IT **149315-20-8** **149383-15-3** **149383-16-4** **149383-22-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)
RN 149315-20-8 CAPLUS
CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26→42)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

RN 149383-16-4 CAPLUS
CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 LRGGHFCGAT LIAPNFVMSA AHCVA

Absolute stereochemistry.







PAGE 2-C



PAGE 3-A



PAGE 3-B

RN 149383-22-2 CAPLUS

CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3→19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d ibib l26 1-2 hitseq

L26 ANSWER 1 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2004:20438 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 140:110118
TITLE: Mammalian CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases
INVENTOR(S): Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallon, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.
PATENT ASSIGNEE(S): Centocor, Inc., USA
SOURCE: PCT Int. Appl., 129 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004002417	A2	20040108	WO 2003-US20347	20030627 <--
WO 2004002417	A3	20041104		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2490409	A1	20040108	CA 2003-2490409	20030627 <--
AU 2003280130	A1	20040119	AU 2003-280130	20030627 <--
EP 1545608	A2	20050629	EP 2003-742272	20030627 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
JP 2006504406	T	20060209	JP 2004-517981	20030627 <--
PRIORITY APPLN. INFO.:			US 2002-392431P P	20020628 <--
			WO 2003-US20347 W	20030627

IT **151679-59-3**
RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(amino acid sequence, mimetibody comprising; mammalian CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.







PAGE 2-B



PAGE 2-C



L26 ANSWER 2 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2003:874784 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 139:358727
TITLE: CAP37/CAP37 peptides for use as bacteriostatics for contact lens and corneal transplants and for treatment of ocular infections
INVENTOR(S): Pereira, Heloise Anne; Chodosh, James; Callegan, Michelle C.
PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA
SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

US 20030206938	A1	20031106	US 2003-423311	20030425 <--
US 7354900	B2	20080408		
WO 2003092718	A2	20031113	WO 2003-US13146	20030428 <--
WO 2003092718	A3	20040401		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

AU 2003239184	A1	20031117	AU 2003-239184	20030428 <--
EP 1503784	A2	20050209	EP 2003-733902	20030428 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK

PRIORITY APPLN. INFO.:	US 2002-378295P	P	20020503 <--
	WO 2003-US13146	W	20030428

IT **151679-59-3**

RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(human CAP37 peptide; CAP37/CAP37 peptides for use as bacteriostatics for contact lens and corneal transplants and for treatment of ocular infections)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> d ibib l26 3-17 hitseq

L26  ANSWER 3 OF 17  CAPLUS  COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER:         2001:816705  CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER:          135:366701
TITLE:                    Fc-domain-modified peptides as therapeutic agents
INVENTOR(S):              Feige, Ulrich; Liu, Chuan-Fa; Cheetham, Janet C.;
                          Boone, Thomas Charles; Gudas, Jean Marie
PATENT ASSIGNEE(S):       Amgen Inc., USA
SOURCE:                   PCT Int. Appl., 176 pp.
                          CODEN: PIXXD2
DOCUMENT TYPE:            Patent
LANGUAGE:                 English
FAMILY ACC. NUM. COUNT:   2
PATENT INFORMATION:

     PATENT NO.           KIND   DATE        APPLICATION NO.          DATE
     ---------------      ----   --------    --------------------     --------
     WO 2001083525         A2    20011108    WO 2001-US14310          20010502 <--
     WO 2001083525         A3    20020718
         W:  AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
             CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM,
             HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS,
             LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO,
             RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN,
             YU, ZA, ZW
         RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
             DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF,
             BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
     CA 2407956            A1    20011108    CA 2001-2407956          20010502 <--
     EP 1278778            A2    20030129    EP 2001-932951           20010502 <--
         R:  AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
             IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
     JP 2003533187         T     20031111    JP 2001-580949           20010502 <--
     AU 2001259432         B2    20050421    AU 2001-259432           20010502 <--
     MX 2002PA10787        A     20030714    MX 2002-PA10787          20021101 <--
     US 20050123548        A1    20050609    US 2003-645784           20030818 <--
     US 20040077022        A1    20040422    US 2003-666696           20030919 <--
     US 20060234307        A1    20061019    US 2006-472070           20060620 <--
PRIORITY APPLN. INFO.:                       US 2000-563286      A    20000503 <--
                                             US 1998-105371P     P    19981023 <--
                                             US 1999-428082      A2   19991022 <--
                                             WO 2001-US14310     W    20010502 <--
                                             US 2003-666696      A1   20030919

IT   151679-59-3
     RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES
     (Uses)
        (Fc-domain-modified peptides as therapeutic agents)
RN   151679-59-3  CAPLUS
CN   L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-
     phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-
     histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-
     L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-  (CA INDEX NAME)
```

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 4 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:782060 CAPLUS <<LOGINID::20081208>>
Correction of: 1997:601254
DOCUMENT NUMBER: 135:287507
Correction of: 127:306552
TITLE: Interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes
AUTHOR(S): Lambros, Maria Polikandritou; Sheu, Eric; Lin, J. S.; Pereira, H. Anne
CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
SOURCE: Biochimica et Biophysica Acta, Biomembranes (1997), 1329(2), 285-290
CODEN: BBBMBS; ISSN: 0005-2736
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **151679-59-3P**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 5 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:824291 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 134:21425
TITLE: Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
INVENTOR(S): Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter G.; Holmes, Darren L.; Thibaudeau, Karen
PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
SOURCE: PCT Int. Appl., 733 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069900	A2	20001123	WO 2000-US13576	20000517 <--
WO 2000069900	A3	20010215		
WO 2000069900	A9	20020704		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373252	A1	20001123	CA 2000-2373252	20000517 <--
CA 2373252	C	20070807		
CA 2373680	A1	20001123	CA 2000-2373680	20000517 <--
CA 2373680	C	20080729		
CA 2499211	A1	20001123	CA 2000-2499211	20000517 <--
CA 2501421	A1	20001123	CA 2000-2501421	20000517 <--
CA 2505617	A1	20001123	CA 2000-2505617	20000517 <--
CA 2623458	A1	20001123	CA 2000-2623458	20000517 <--
WO 2000070665	A2	20001123	WO 2000-IB763	20000517 <--
WO 2000070665	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1105409	A2	20010613	EP 2000-936023	20000517 <--
EP 1105409	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EP 1171582	A2	20020116	EP 2000-929748	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1264840	A1	20021211	EP 2002-14617	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

IE, SI, LT, LV, FI, RO, MK, CY, AL

JP 2003500341	T	20030107	JP 2000-619018		20000517 <--
JP 2003508350	T	20030304	JP 2000-618316		20000517 <--
AU 765753	B2	20030925	AU 2000-51393		20000517 <--
EP 1591453	A1	20051102	EP 2005-105384		20000517 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

CN 1698881	A	20051123	CN 2005-10005990		20000517 <--
EP 1598365	A1	20051123	EP 2005-105387		20000517 <--

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

EP 1623994	A2	20060208	EP 2005-108328		20000517 <--
EP 1623994	A3	20080716			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL

AT 318835	T	20060315	AT 2000-936023		20000517 <--
PT 1105409	T	20060731	PT 2000-936023		20000517 <--
ES 2257298	T3	20060801	ES 2000-936023		20000517 <--
CN 101289500	A	20081022	CN 2008-10091504		20000517 <--
US 6849714	B1	20050201	US 2000-623548		20000905 <--
US 6514500	B1	20030204	US 2000-657332		20000907 <--
US 7090851	B1	20060815	US 2000-657336		20000907 <--
US 7144854	B1	20061205	US 2000-657431		20000907 <--
ZA 2001006676	A	20020719	ZA 2001-6676		20010814 <--
ZA 2001009110	A	20020613	ZA 2001-9110		20011105 <--
US 20030108567	A1	20030612	US 2002-287892		20021104 <--
US 6821949	B2	20041123			
US 20030108568	A1	20030612	US 2002-288340		20021104 <--
US 6887849	B2	20050503			
US 20040127398	A1	20040701	US 2003-722733		20031125 <--
US 20040138100	A1	20040715	US 2003-723099		20031125 <--
US 20050176641	A1	20050811	US 2005-40810		20050121 <--
US 20050176643	A1	20050811	US 2005-67556		20050225 <--
JP 2005263807	A	20050929	JP 2005-115175		20050412 <--
JP 2005239736	A	20050908	JP 2005-140407		20050512 <--
JP 2005255689	A	20050922	JP 2005-151458		20050524 <--
JP 4116016	B2	20080709			
US 20060009377	A1	20060112	US 2005-170967		20050629 <--
US 20060058235	A1	20060316	US 2005-215967		20050830 <--
JP 2006151986	A	20060615	JP 2005-361126		20051214 <--
US 20060135426	A1	20060622	US 2005-304446		20051214 <--
US 20060135428	A1	20060622	US 2006-350703		20060208 <--
US 20080194486	A1	20080814	US 2007-923222		20071024 <--
US 20080199532	A1	20080821	US 2007-926843		20071029 <--
JP 2008101021	A	20080501	JP 2007-325307		20071217 <--
JP 2008110986	A	20080515	JP 2008-8554		20080117 <--
JP 2008150384	A	20080703	JP 2008-8555		20080117 <--
PRIORITY APPLN. INFO.:			US 1999-134406P	P	19990517 <--
			US 1999-153406P	P	19990910 <--
			US 1999-159783P	P	19991015 <--
			US 1999-134406	A	19990517 <--
			US 1999-153406	A	19990910 <--
			US 1999-159783	A	19991015 <--
			CA 2000-2363712	A3	20000517 <--
			CA 2000-2373680	A3	20000517 <--
			CN 2000-807671	A3	20000517 <--

EP	2000-932570	A3	20000517 <--
EP	2000-936023	A3	20000517 <--
JP	2000-618316	A3	20000517 <--
JP	2000-618318	A3	20000517 <--
JP	2000-618327	A3	20000517 <--
JP	2000-619018	A3	20000517 <--
WO	2000-IB763	W	20000517 <--
WO	2000-US13576	W	20000517 <--
US	2000-623543	A1	20000905 <--
US	2000-623548	A1	20000905 <--
US	2000-657276	A2	20000907 <--
US	2000-657332	A3	20000907 <--
US	2000-657431	A1	20000907 <--
US	2002-400199P	P	20020731 <--
US	2002-400413P	P	20020731 <--
US	2002-288340	A1	20021104
WO	2003-CA1097	W	20030729
US	2003-471348	A1	20030908
US	2003-722733	A1	20031125
US	2005-40810	A2	20050121
US	2005-67556	A1	20050225
US	2005-170967	A1	20050629
US	2005-215967	A1	20050830

IT **151679-59-3**
RL: PRP (Properties)
(unclaimed sequence; protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 6 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:725850 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 133:295374
TITLE: Lipopolysaccharide immunoassay and test device
INVENTOR(S): Badley, Robert Andrew; Hughes, Glen; Zak, Krzysztof Wojciech
PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever N. V.; Hindustan Lever Limited
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060354	A1	20001012	WO 2000-EP2869	20000403 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368975	A1	20001012	CA 2000-2368975	20000403 <--
EP 1166113	A1	20020102	EP 2000-926787	20000403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541457	T	20021203	JP 2000-609793	20000403 <--
AU 763916	B2	20030807	AU 2000-45415	20000403 <--
US 20030054422	A1	20030320	US 2002-131433	20020423 <--

PRIORITY APPLN. INFO.:
EP 1999-302711 A 19990407 <--
WO 2000-EP2869 W 20000403 <--
US 2000-545180 A3 20000407 <--

IT **151679-59-3**
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(antibody and lipopolysaccharide binding protein for immunodetection of lipopolysaccharide and clin. diagnosis of gram-neg. bacterial infection)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 7 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:587063 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 133:187935
TITLE: Antibacterial CAP37 peptides and therapeutic use thereof
INVENTOR(S): Pereira, H. Anne
PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA
SOURCE: U.S., 40 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6107460	A	20000822	US 1999-258934	19990301 <--
US 6514701	B1	20030204	US 2000-619283	20000719 <--
US 20040048792	A1	20040311	US 2002-328125	20021220 <--
US 6730659	B2	20040504		

PRIORITY APPLN. INFO.: US 1999-258934 A3 19990301 <--
US 2000-619283 A3 20000719 <--
OTHER SOURCE(S): MARPAT 133:187935
IT **151679-59-3** **288855-83-4** **288856-01-9**
288856-02-0 **288856-03-1** **288856-10-0**
288856-11-1 **288856-12-2** **288856-14-4**
288856-15-5 **288856-16-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibacterial CAP37 peptides and therapeutic use thereof)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288855-83-4 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA AHCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







RN 288856-01-9 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCAGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-02-0 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGAA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-03-1 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCAAA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-10-0 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-threonyl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ATCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-D

RN 288856-11-1 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-leucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFLMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-12-2 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFIMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-14-4 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

tyrosyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHYCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B




NH
S
(CH2)3
N
H
NH2
O
Ph


O
H
N
H2N
S
CO2H
O



SMe

RN 288856-15-5 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-tyrosyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARYVMTA ASCFQ

Absolute stereochemistry.







PAGE 1-C



PAGE 2-A







PAGE 2-B





RN 288856-16-6 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-tyrosyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCYQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 8 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:291095 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 132:329919
TITLE: Modified peptides containing an antibody Fc domain as therapeutic agents
INVENTOR(S): Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 608 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024782	A2	20000504	WO 1999-US25044	19991025 <--
WO 2000024782	A3	20020606		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6660843	B1	20031209	US 1999-428082	19991022	<--
CA 2347131	A1	20000504	CA 1999-2347131	19991025	<--
EP 1144454	A2	20011017	EP 1999-971003	19991025	<--
EP 1144454	A3	20020911			
EP 1144454	B1	20071212			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK

CN 1331701	A	20020116	CN 1999-814727	19991025	<--
CN 1310948	C	20070418			
BR 9914708	A	20020716	BR 1999-14708	19991025	<--
HU 2002003506	A2	20030228	HU 2002-3506	19991025	<--
JP 2003512011	T	20030402	JP 2000-578351	19991025	<--
AU 767725	B2	20031120	AU 2000-12322	19991025	<--
NZ 510888	A	20040130	NZ 1999-510888	19991025	<--
NZ 528882	A	20050624	NZ 1999-528882	19991025	<--
CN 1721447	A	20060118	CN 2005-10082591	19991025	<--
CN 1746189	A	20060315	CN 2005-10083696	19991025	<--
CN 100384880	C	20080430			
CN 1746190	A	20060315	CN 2005-10083697	19991025	<--
CN 1781945	A	20060607	CN 2005-10081495	19991025	<--
CN 100384879	C	20080430			
CN 1781946	A	20060607	CN 2005-10081496	19991025	<--
CN 1781947	A	20060607	CN 2005-10081497	19991025	<--
CN 1908014	A	20070207	CN 2005-10081952	19991025	<--
AT 380828	T	20071215	AT 1999-971003	19991025	<--
ES 2299278	T3	20080516	ES 1999-971003	19991025	<--
ZA 2001002753	A	20020611	ZA 2001-2753	20010404	<--
MX 2001PA03873	A	20031014	MX 2001-PA3873	20010417	<--
NO 2001001963	A	20010621	NO 2001-1963	20010420	<--
BG 105461	A	20030430	BG 2001-105461	20010424	<--
HK 1042097	A1	20080403	HK 2002-102701	20020410	<--
US 20040044188	A1	20040304	US 2003-609217	20030627	<--
US 7166707	B2	20070123			
US 20040053845	A1	20040318	US 2003-632388	20030731	<--
US 7189827	B2	20070313			
US 20040071712	A1	20040415	US 2003-645761	20030818	<--
US 20050123548	A1	20050609	US 2003-645784	20030818	<--
US 20040057953	A1	20040325	US 2003-651723	20030829	<--
US 7169905	B2	20070130			
US 20040087778	A1	20040506	US 2003-653048	20030829	<--
US 7186810	B2	20070306			
US 20040077022	A1	20040422	US 2003-666696	20030919	<--
AU 2004200687	A1	20040318	AU 2004-200687	20040220	<--
AU 2004200687	B2	20070510			
AU 2004200690	A1	20040318	AU 2004-200690	20040220	<--
AU 2004200690	B2	20070510			
AU 2004200691	A1	20040318	AU 2004-200691	20040220	<--
AU 2004200691	B2	20070329			

US 20060234307	A1	20061019	US 2006-472070		20060620 <--
JP 2007084555	A	20070405	JP 2006-288325		20061024 <--
JP 2007084556	A	20070405	JP 2006-288346		20061024 <--
JP 2007084557	A	20070405	JP 2006-288383		20061024 <--
JP 2007084558	A	20070405	JP 2006-288397		20061024 <--
JP 2007091746	A	20070412	JP 2006-288324		20061024 <--
JP 2007091747	A	20070412	JP 2006-288347		20061024 <--
JP 2007089586	A	20070412	JP 2006-288382		20061024 <--
JP 2007105044	A	20070426	JP 2006-288398		20061024 <--
US 20070049532	A1	20070301	US 2006-591002		20061031 <--
KR 2007050977	A	20070516	KR 2007-706958		20070327 <--
KR 2007050978	A	20070516	KR 2007-706961		20070327 <--
PRIORITY APPLN. INFO.:			US 1998-105371P	P	19981023 <--
			US 1999-428082	A	19991022 <--
			AU 2000-12322	A3	19991025 <--
			CN 1999-814727	A3	19991025 <--
			JP 2000-578351	A3	19991025 <--
			WO 1999-US25044	W	19991025 <--
			US 2000-563286	A1	20000503 <--
			KR 2001-704982	A3	20010420 <--
			US 2003-645761	A3	20030818
			US 2003-666696	A1	20030919
			AU 2004-200687	A	20040220

IT **151679-59-3D**, fusion protein with IgG1 Fc domain
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CAP37 mimetic/LPS binding; modified peptides containing an antibody Fc domain as therapeutic agents)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 9 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:601254 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:306552
ORIGINAL REFERENCE NO.: 127:59951a
TITLE: Interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes
AUTHOR(S): Polikandritou Lambros, Maria; Sheu, Eric; Lin, J. S.; Pereira, H. Anne
CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
SOURCE: Biochimica et Biophysica Acta, Biomembranes (**1997**), 1329(2), 285-290
CODEN: BBBMBS; ISSN: 0005-2736
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **151679-59-3P**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 14 THERE ARE 14 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 10 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:408609 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:148252
ORIGINAL REFERENCE NO.: 127:28629a
TITLE: A synthetic lipopolysaccharide-binding peptide based on the neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats
AUTHOR(S): Brackett, Daniel J.; Lerner, Megan R.; Lacquement, Melissa A.; He, Rong; Pereira, H. Anne
CORPORATE SOURCE: Department of Surgery, University of Oklahoma Health Sciences Center, Oklahoma City, OK, 73190, USA
SOURCE: Infection and Immunity (**1997**), 65(7), 2803-2811
CODEN: INFIBR; ISSN: 0019-9567
PUBLISHER: American Society for Microbiology
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **151679-59-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); BIOL (Biological study)
(synthetic lipopolysaccharide-binding peptide based on neutrophil-derived protein CAP37 prevents endotoxin-induced responses in conscious rats)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 75 THERE ARE 75 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L26 ANSWER 11 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1997:344807 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 127:13456
ORIGINAL REFERENCE NO.: 127:2623a,2626a
TITLE: Method and composition for the treatment of septic shock
INVENTOR(S): Pereira, Heloise A.
PATENT ASSIGNEE(S): University of Oklahoma, USA
SOURCE: U.S., 29 pp., Cont.-in-part of U.S. 5,607,916.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--
PRIORITY APPLN. INFO.:			US 1989-375739 B2	19890705 <--
			US 1990-543151 B2	19900625 <--
			US 1992-855417 A1	19920319 <--
			US 1992-969931 A2	19921030 <--
			US 1994-235399 A2	19940429 <--
			US 1992-939931 A2	19921030 <--
			US 1995-482328 A1	19950607 <--
			US 1997-840519 A1	19970421 <--

IT **151679-59-3**
RL: BAC (Biological activity or effector, except adverse); BPR (Biological process); BSU (Biological study, unclassified); PEP (Physical, engineering or chemical process); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(method and composition for the treatment of septic shock)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 12 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1997:204303 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 126:207540
ORIGINAL REFERENCE NO.: 126:40001a
TITLE: Method and composition using lipopolysaccharide-binding peptide derived from CAP37 protein for the treatment of septic shock
INVENTOR(S): Pereira, Heloise A.; Brackett, Daniel J.; Lerner, Megan R.
PATENT ASSIGNEE(S): Board of Regents of the University of Oklahoma, USA
SOURCE: U.S., 19 pp., Cont.-in-part of U.S.5,458,874.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.		DATE	
US 5607916	A	19970304	US 1994-235399		19940429	<--
US 5484885	A	19960116	US 1992-855417		19920319	<--
US 5458874	A	19951017	US 1992-969931		19921030	<--
US 5650392	A	19970722	US 1995-455485		19950531	<--
US 5627262	A	19970506	US 1995-482328		19950607	<--
US 5877151	A	19990302	US 1997-840519		19970421	<--
US 6071879	A	20000606	US 1999-260373		19990301	<--
PRIORITY APPLN. INFO.:			US 1989-375739	B2	19890705	<--
			US 1990-543151	B2	19900625	<--
			US 1992-855417	A1	19920319	<--
			US 1992-969931	A2	19921030	<--
			US 1992-939931	A2	19921030	<--
			US 1994-235399	A3	19940429	<--
			US 1995-482328	A1	19950607	<--
			US 1997-840519	A1	19970421	<--

IT **151679-59-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(lipopolysaccharide-binding peptide derived from CAP37 protein for the treatment of septic shock)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 13 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:137923 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 124:315067
ORIGINAL REFERENCE NO.: 124:58442h,58443a
TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
INVENTOR(S): Pereira, Heloise A.; Spitznagel, John K.
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: U.S., 50 pp. Cont.-in-part of U.S. Ser. No. 543,151, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5484885	A	19960116	US 1992-855417	19920319 <--
US 5458874	A	19951017	US 1992-969931	19921030 <--
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--
W: AU, CA, JP				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE				
AU 9348089	A	19931021	AU 1993-48089	19930319 <--
US 5607916	A	19970304	US 1994-235399	19940429 <--
US 5650392	A	19970722	US 1995-455485	19950531 <--
US 5627262	A	19970506	US 1995-482328	19950607 <--
US 5877151	A	19990302	US 1997-840519	19970421 <--
US 6071879	A	20000606	US 1999-260373	19990301 <--

PRIORITY APPLN. INFO.:

US 1989-375739	B2	19890705 <--
US 1990-543151	B2	19900625 <--
US 1992-855417	A1	19920319 <--
US 1992-939931	A2	19921030 <--
US 1992-969931	A2	19921030 <--
WO 1993-US2580	A	19930319 <--
US 1994-235399	A3	19940429 <--
US 1995-482328	A1	19950607 <--
US 1997-840519	A1	19970421 <--

IT **151679-59-3P**
RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(chemotactic/antibiotic/lipopolysaccharide-binding peptide fragments of CAP37 for treating wounds, tumors, and infections)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 14 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1996:32761 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 124:114140
ORIGINAL REFERENCE NO.: 124:21195a,21198a
TITLE: A cationic antimicrobial peptide enhances the infectivity of Coxiella burnetii
AUTHOR(S): Aragon, A. S.; Pereira, H. A.; Baca, O. G.
CORPORATE SOURCE: Biology Department, University of New Mexico, Albuquerque, NM, 8713-1091, USA
SOURCE: Acta Virologica (English Edition) (**1995**), 39(4), 223-6
CODEN: AVIRA2; ISSN: 0001-723X
PUBLISHER: Slovak Academic Press
DOCUMENT TYPE: Journal
LANGUAGE: English

IT **151679-59-3**
RL: ADV (Adverse effect, including toxicity); BIOL (Biological study) (CAP3720-44 (a synthetic peptide based on the 37-Kd human neutrophil granule-associated cationic antimicrobial protein, CAP37) enhances the infectivity of Coxiella burnetii)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 15 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1996:17399 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 124:84820
ORIGINAL REFERENCE NO.: 124:15949a,15952a
TITLE: Sperm immobilizing activity of a synthetic bioactive peptide 20-44 of 37-kDa cationic antimicrobial protein (CAP37) of human neutrophils
AUTHOR(S): D'Cruz, Osmond J.; Pereira, H. Anne; Haas, Gilbert G. Jr.
CORPORATE SOURCE: Health Sciences Center, University Oklahoma, Oklahoma City, OK, 73190, USA
SOURCE: Journal of Andrology (**1995**), 16(5), 432-40
CODEN: JOAND3; ISSN: 0196-3635
PUBLISHER: American Society of Andrology
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **151679-59-3**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

study, unclassified); BIOL (Biological study)
(sperm immobilization by peptide 20-44 fragment of CAP37 of human neutrophils)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.







PAGE 2-B



PAGE 2-C



L26 ANSWER 16 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 1994:563 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 120:563
ORIGINAL REFERENCE NO.: 120:135a,138a
TITLE: Chemotactic, antibiotic and lipopolysaccharide-binding peptide fragments of CAP37
INVENTOR(S): Pereira, Heloise Anne; Spitznagel, John K.
PATENT ASSIGNEE(S): Emory University, USA
SOURCE: PCT Int. Appl., 108 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9319087	A1	19930930	WO 1993-US2580	19930319 <--

W: AU, CA, JP
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE

US 5484885	A	19960116	US 1992-855417		19920319 <--
AU 9348089	A	19931021	AU 1993-48089		19930319 <--
PRIORITY APPLN. INFO.:			US 1992-855417	A	19920319 <--
			US 1989-375739	B2	19890705 <--
			US 1990-543151	B2	19900625 <--
			WO 1993-US2580	A	19930319 <--

IT **151705-32-7 151769-18-5 152699-65-5**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of)

RN 151705-32-7 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminyl-L-glutaminyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQQRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.







PAGE 2-A



PAGE 2-B



RN 151769-18-5 CAPLUS

CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 152699-65-5 CAPLUS

CN L-Glutamine, L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 FCGGALIHAR FVMTAASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B







IT **151679-59-3**
RL: BIOL (Biological study)
(of chemotactic protein, of neutrophil, bactericidal and lipopolysaccharide-binding activity of)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1. NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L26 ANSWER 17 OF 17 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1993:515274 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 119:115274
ORIGINAL REFERENCE NO.: 119:20733a,20736a
TITLE: Synthetic bactericidal peptide based on CAP37: A 37-kDa human neutrophil granule-associated cationic antimicrobial protein chemotactic for monocytes
AUTHOR(S): Pereira, H. Anne; Erdem, Imre; Pohl, Jan; Spitznagel, John K.
CORPORATE SOURCE: Sch. Med., Emory Univ., Atlanta, GA, 30322, USA
SOURCE: Proceedings of the National Academy of Sciences of the United States of America (**1993**), 90(10), 4733-7
CODEN: PNASA6; ISSN: 0027-8424
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **149315-20-8** **149383-15-3** **149383-16-4** **149383-22-2**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(bactericidal activity of, azurocidin bactericidal domain of neutrophil granules of humans in relation to)
RN 149315-20-8 CAPLUS
CN L-Glutamine, L-isoleucyl-L-valylglycylglycyl-L-arginyl-L-lysyl-L-alanyl-L-arginyl-L-prolyl-L-arginyl-L-glutaminyl-L-phenylalanyl-L-prolyl-L-phenylalanyl-L-leucyl-L-alanyl-L-seryl-L-isoleucyl-L-glutaminyl-L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (26→42)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 IVGGRKARPR QFPFLASIQN QGRHFCGGAL IHARFVMTAA SCFQ

RN 149383-15-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

RN 149383-16-4 CAPLUS
CN L-Alanine, L-leucyl-L-arginylglycylglycyl-L-histidyl-L-phenylalanyl-L-cysteinylglycyl-L-alanyl-L-threonyl-L-leucyl-L-isoleucyl-L-alanyl-L-prolyl-L-asparaginyl-L-phenylalanyl-L-valyl-L-methionyl-L-seryl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-valyl-, cyclic (7→23)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 LRGGHFCGAT LIAPNFVMSA AHCVA

Absolute stereochemistry.





PAGE 2-B



PAGE 2-C



PAGE 3-A



PAGE 3-B

RN 149383-22-2 CAPLUS
CN L-Glutamine, L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl-, cyclic (3→19)-disulfide (9CI) (CA INDEX NAME)

SEQ 1 HFCGGALIHA RFVMTAASCF Q

=> d his ful que sta
'QUE' IS NOT VALID HERE
For an explanation, enter "HELP DISPLAY HISTORY".

=> d his ful

(FILE 'HOME' ENTERED AT 09:00:30 ON 08 DEC 2008)

FILE 'REGISTRY' ENTERED AT 09:00:39 ON 08 DEC 2008
L1 0 SEA PLU=ON [RK][ARNQGHILKMFPSTWVY]C[AGS][TAGS][HILMFPTVWY][HILMFPTVWY][AGSHILMFPTVWYNQ][ARNQGHILKMFPSTWVY][RKHILMFPTVWYNQ][HILMFPTVWY][HILMFPTVWY][HILMFPTVWY][SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP
L2 4577 SEA PLU=ON [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY]/SQSP
L3 32 SEA PLU=ON L2 AND SQL<=29

```
L4          37 SEA PLU=ON  ^.{1-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFP
               TVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RK
               HILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY]
               [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY].{1-5}/SQSP
L5          35 SEA PLU=ON  ^.{2-5}[ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFP
               TVWY]){2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RK
               HILMFPTVWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY]
               [AGSHILMFPTVWYNQ]C[AGSHILMFPTVWY].{1-5}/SQSP
L6        1428 SEA PLU=ON  [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){
               2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][PRQ][RKHILMFPTVWYNQ]([HILMFP
               TVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[AG
               SHILMFPTVWY]/SQSP
L7         277 SEA PLU=ON  [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){
               2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPT
               VWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHIL
               MFPTVWYNQ]C[AGSHILMFPTVWY][RA]/SQSP
L8         251 SEA PLU=ON  [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){
               2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][RKHILMFPT
               VWYNQ]([HILMFPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHIL
               MFPTVWYNQ]C[AGSHILMFPTVWY]Q/SQSP
L9        1447 SEA PLU=ON  [ANRQGHILKMFPSTWYV]C([AGS]){2}[TAGS]([HILMFPTVWY]){
               2}[AGSHILMFPTVWYANRQGHILKMFPSTWYV][ANRQGHILKMFPSTWYV][NQ]([HILM
               FPTVWY]){3}[SHILMFPTVWY][AGS][AGSHILMFPTVWY][AGSHILMFPTVWYNQ]C[
               AGSHILMFPTVWY]/SQSP
L10         35 SEA PLU=ON  L2 AND SQL=<44
L11         12 SEA PLU=ON  L10 AND L6
L12         11 SEA PLU=ON  L10 AND L7
L13         19 SEA PLU=ON  L10 AND L8
L14          5 SEA PLU=ON  L10 AND L9
L15         33 SEA PLU=ON  L11 OR L12 OR L13 OR L14

    FILE 'CAPLUS' ENTERED AT 09:08:37 ON 08 DEC 2008
L16         26 SEA PLU=ON  L15
L17         17 SEA PLU=ON  L16 AND PD<=20030814
L18         15 SEA PLU=ON  L16 AND PRD<=20030814
L19         20 SEA PLU=ON  L16 AND ( PD<=20020814 OR PRD<=20020814)
               D L19 1-20 IBIB HITSEQ
L20          3 SEA PLU=ON  L11
L21          3 SEA PLU=ON  L12
L22         23 SEA PLU=ON  L13
L23          3 SEA PLU=ON  L14
L24          2 SEA PLU=ON  L19 AND L20
L25          2 SEA PLU=ON  L19 AND L21
L26         17 SEA PLU=ON  L19 AND L22
L27          2 SEA PLU=ON  L19 AND L23
L28          4 SEA PLU=ON  L24 OR L25 OR L27
               D IBIB L24 1-2
               D IBIB L24 1-2 HITSEQ
               D IBIB L25 1-2 HITSEQ
               D IBIB L27 1-2 HITSEQ
               D IBIB L26 1-2 HITSEQ
               D IBIB L26 3-17 HITSEQ


    FILE HOME
```

FILE REGISTRY
Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1
DICTIONARY FILE UPDATES: 5 DEC 2008 HIGHEST RN 1080697-25-1

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH July 5, 2008.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

FILE CAPLUS

FILE COVERS 1907 - 8 Dec 2008 VOL 149 ISS 24
FILE LAST UPDATED: 7 Dec 2008 (20081207/ED)

Caplus now includes complete International Patent Classification (IPC) reclassification data for the third quarter of 2008.

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/legal/infopolicy.html

=> log y

PAGE 2-B



PAGE 2-C



L19 ANSWER 2 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER:	2004:20438 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER:	140:110118
TITLE:	Mammalian CH1 deleted mimetibodies, compositions, methods and uses for diagnosis and therapy of human diseases
INVENTOR(S):	Heavner, George A.; Knight, David M.; Ghrayeb, John; Scallon, Bernard J.; Nesspor, Thomas C.; Kutoloski, Karen A.
PATENT ASSIGNEE(S):	Centocor, Inc., USA
SOURCE:	PCT Int. Appl., 129 pp. CODEN: PIXXD2
DOCUMENT TYPE:	Patent
LANGUAGE:	English
FAMILY ACC. NUM. COUNT:	2
PATENT INFORMATION:	

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE

WO 2004002417	A2	20040108	WO 2003-US20347	20030627 <--
WO 2004002417	A3	20041104		
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW			
RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
CA 2490409	A1	20040108	CA 2003-2490409	20030627 <--
AU 2003280130	A1	20040119	AU 2003-280130	20030627 <--
EP 1545608	A2	20050629	EP 2003-742272	20030627 <--
R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK			
JP 2006504406	T	20060209	JP 2004-517981	20030627 <--
PRIORITY APPLN. INFO.:			US 2002-392431P P	20020628 <--
			WO 2003-US20347 W	20030627

IT **151679-59-3**

RL: DGN (Diagnostic use); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)

(amino acid sequence, mimetibody comprising; mammalian CH1 deleted mimetibodies, compns., methods and uses for diagnosis and therapy of human diseases)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 3 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2003:874784 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 139:358727
TITLE: CAP37/CAP37 peptides for use as bacteriostatics for contact lens and corneal transplants and for treatment of ocular infections
INVENTOR(S): Pereira, Heloise Anne; Chodosh, James; Callegan, Michelle C.
PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA
SOURCE: U.S. Pat. Appl. Publ., 31 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20030206938	A1	20031106	US 2003-423311	20030425 <--
US 7354900	B2	20080408		
WO 2003092718	A2	20031113	WO 2003-US13146	20030428 <--
WO 2003092718	A3	20040401		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003239184	A1	20031117	AU 2003-239184	20030428 <--
EP 1503784	A2	20050209	EP 2003-733902	20030428 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2002-378295P P 20020503 <--
WO 2003-US13146 W 20030428

IT **151679-59-3**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(human CAP37 peptide; CAP37/CAP37 peptides for use as bacteriostatics for contact lens and corneal transplants and for treatment of ocular infections)

RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 33 THERE ARE 33 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 4 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:816705 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 135:366701
TITLE: Fc-domain-modified peptides as therapeutic agents
INVENTOR(S): Feige, Ulrich; Liu, Chuan-Fa; Cheetham, Janet C.; Boone, Thomas Charles; Gudas, Jean Marie
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 176 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001083525	A2	20011108	WO 2001-US14310	20010502 <--
WO 2001083525	A3	20020718		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2407956	A1	20011108	CA 2001-2407956	20010502 <--
EP 1278778	A2	20030129	EP 2001-932951	20010502 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2003533187	T	20031111	JP 2001-580949	20010502 <--
AU 2001259432	B2	20050421	AU 2001-259432	20010502 <--
MX 2002PA10787	A	20030714	MX 2002-PA10787	20021101 <--
US 20050123548	A1	20050609	US 2003-645784	20030818 <--
US 20040077022	A1	20040422	US 2003-666696	20030919 <--
US 20060234307	A1	20061019	US 2006-472070	20060620 <--

PRIORITY APPLN. INFO.:	US 2000-563286	A	20000503 <--
	US 1998-105371P	P	19981023 <--
	US 1999-428082	A2	19991022 <--
	WO 2001-US14310	W	20010502 <--
	US 2003-666696	A1	20030919

IT **151679-59-3**
RL: PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(Fc-domain-modified peptides as therapeutic agents)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 5 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2001:782060 CAPLUS <<LOGINID::20081208>>
Correction of: 1997:601254
DOCUMENT NUMBER: 135:287507
Correction of: 127:306552
TITLE: Interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes
AUTHOR(S): Lambros, Maria Polikandritou; Sheu, Eric; Lin, J. S.; Pereira, H. Anne
CORPORATE SOURCE: College of Pharmacy, University of Oklahoma Health Sciences Center, Oklahoma City, OK, USA
SOURCE: Biochimica et Biophysica Acta, Biomembranes (**1997**), 1329(2), 285-290
CODEN: BBBMBS; ISSN: 0005-2736
PUBLISHER: Elsevier B.V.
DOCUMENT TYPE: Journal
LANGUAGE: English
IT **151679-59-3P**
RL: BPR (Biological process); BSU (Biological study, unclassified); PRP (Properties); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); PROC (Process); USES (Uses)
(interaction of a synthetic peptide based on the neutrophil-derived antimicrobial protein CAP37 with dipalmitoyl-phosphatidylcholine membranes)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 6 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:824291 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 134:21425
TITLE: Protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components
INVENTOR(S): Bridon, Dominique P.; Ezrin, Alan M.; Milner, Peter G.; Holmes, Darren L.; Thibaudeau, Karen
PATENT ASSIGNEE(S): Conjuchem, Inc., Can.
SOURCE: PCT Int. Appl., 733 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 5
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000069900	A2	20001123	WO 2000-US13576	20000517 <--
WO 2000069900	A3	20010215		
WO 2000069900	A9	20020704		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2373252	A1	20001123	CA 2000-2373252	20000517 <--
CA 2373252	C	20070807		
CA 2373680	A1	20001123	CA 2000-2373680	20000517 <--
CA 2373680	C	20080729		
CA 2499211	A1	20001123	CA 2000-2499211	20000517 <--
CA 2501421	A1	20001123	CA 2000-2501421	20000517 <--
CA 2505617	A1	20001123	CA 2000-2505617	20000517 <--
CA 2623458	A1	20001123	CA 2000-2623458	20000517 <--
WO 2000070665	A2	20001123	WO 2000-IB763	20000517 <--
WO 2000070665	A3	20010419		
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
EP 1105409	A2	20010613	EP 2000-936023	20000517 <--
EP 1105409	B1	20060301		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY				
EP 1171582	A2	20020116	EP 2000-929748	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
EP 1264840	A1	20021211	EP 2002-14617	20000517 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,				

	IE, SI, LT, LV, FI, RO, MK, CY, AL					
JP	2003500341	T	20030107	JP	2000-619018	20000517 <--
JP	2003508350	T	20030304	JP	2000-618316	20000517 <--
AU	765753	B2	20030925	AU	2000-51393	20000517 <--
EP	1591453	A1	20051102	EP	2005-105384	20000517 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
CN	1698881	A	20051123	CN	2005-10005990	20000517 <--
EP	1598365	A1	20051123	EP	2005-105387	20000517 <--
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
EP	1623994	A2	20060208	EP	2005-108328	20000517 <--
EP	1623994	A3	20080716			
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL					
AT	318835	T	20060315	AT	2000-936023	20000517 <--
PT	1105409	T	20060731	PT	2000-936023	20000517 <--
ES	2257298	T3	20060801	ES	2000-936023	20000517 <--
CN	101289500	A	20081022	CN	2008-10091504	20000517 <--
US	6849714	B1	20050201	US	2000-623548	20000905 <--
US	6514500	B1	20030204	US	2000-657332	20000907 <--
US	7090851	B1	20060815	US	2000-657336	20000907 <--
US	7144854	B1	20061205	US	2000-657431	20000907 <--
ZA	2001006676	A	20020719	ZA	2001-6676	20010814 <--
ZA	2001009110	A	20020613	ZA	2001-9110	20011105 <--
US	20030108567	A1	20030612	US	2002-287892	20021104 <--
US	6821949	B2	20041123			
US	20030108568	A1	20030612	US	2002-288340	20021104 <--
US	6887849	B2	20050503			
US	20040127398	A1	20040701	US	2003-722733	20031125 <--
US	20040138100	A1	20040715	US	2003-723099	20031125 <--
US	20050176641	A1	20050811	US	2005-40810	20050121 <--
US	20050176643	A1	20050811	US	2005-67556	20050225 <--
JP	2005263807	A	20050929	JP	2005-115175	20050412 <--
JP	2005239736	A	20050908	JP	2005-140407	20050512 <--
JP	2005255689	A	20050922	JP	2005-151458	20050524 <--
JP	4116016	B2	20080709			
US	20060009377	A1	20060112	US	2005-170967	20050629 <--
US	20060058235	A1	20060316	US	2005-215967	20050830 <--
JP	2006151986	A	20060615	JP	2005-361126	20051214 <--
US	20060135426	A1	20060622	US	2005-304446	20051214 <--
US	20060135428	A1	20060622	US	2006-350703	20060208 <--
US	20080194486	A1	20080814	US	2007-923222	20071024 <--
US	20080199532	A1	20080821	US	2007-926843	20071029 <--
JP	2008101021	A	20080501	JP	2007-325307	20071217 <--
JP	2008110986	A	20080515	JP	2008-8554	20080117 <--
JP	2008150384	A	20080703	JP	2008-8555	20080117 <--
PRIORITY APPLN. INFO.:				US	1999-134406P	P 19990517 <--
				US	1999-153406P	P 19990910 <--
				US	1999-159783P	P 19991015 <--
				US	1999-134406	A 19990517 <--
				US	1999-153406	A 19990910 <--
				US	1999-159783	A 19991015 <--
				CA	2000-2363712	A3 20000517 <--
				CA	2000-2373680	A3 20000517 <--
				CN	2000-807671	A3 20000517 <--

EP 2000-932570	A3	20000517 <--
EP 2000-936023	A3	20000517 <--
JP 2000-618316	A3	20000517 <--
JP 2000-618318	A3	20000517 <--
JP 2000-618327	A3	20000517 <--
JP 2000-619018	A3	20000517 <--
WO 2000-IB763	W	20000517 <--
WO 2000-US13576	W	20000517 <--
US 2000-623543	A1	20000905 <--
US 2000-623548	A1	20000905 <--
US 2000-657276	A2	20000907 <--
US 2000-657332	A3	20000907 <--
US 2000-657431	A1	20000907 <--
US 2002-400199P	P	20020731 <--
US 2002-400413P	P	20020731 <--
US 2002-288340	A1	20021104
WO 2003-CA1097	W	20030729
US 2003-471348	A1	20030908
US 2003-722733	A1	20031125
US 2005-40810	A2	20050121
US 2005-67556	A1	20050225
US 2005-170967	A1	20050629
US 2005-215967	A1	20050830

IT **151679-59-3**
RL: PRP (Properties)
(unclaimed sequence; protection of endogenous therapeutic peptides from peptidase activity through conjugation to blood components)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



L19 ANSWER 7 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2000:725850 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 133:295374
TITLE: Lipopolysaccharide immunoassay and test device
INVENTOR(S): Badley, Robert Andrew; Hughes, Glen; Zak, Krzysztof Wojciech
PATENT ASSIGNEE(S): Unilever PLC, UK; Unilever N. V.; Hindustan Lever Limited
SOURCE: PCT Int. Appl., 40 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000060354	A1	20001012	WO 2000-EP2869	20000403 <--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2368975	A1	20001012	CA 2000-2368975	20000403 <--
EP 1166113	A1	20020102	EP 2000-926787	20000403 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002541457	T	20021203	JP 2000-609793	20000403 <--
AU 763916	B2	20030807	AU 2000-45415	20000403 <--
US 20030054422	A1	20030320	US 2002-131433	20020423 <--
PRIORITY APPLN. INFO.:			EP 1999-302711 A	19990407 <--
			WO 2000-EP2869 W	20000403 <--
			US 2000-545180 A3	20000407 <--

IT **151679-59-3**
RL: ARG (Analytical reagent use); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); ANST (Analytical study); BIOL (Biological study); USES (Uses)
(antibody and lipopolysaccharide binding protein for immunodetection of lipopolysaccharide and clin. diagnosis of gram-neg. bacterial infection)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 8 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:587063 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 133:187935
TITLE: Antibacterial CAP37 peptides and therapeutic use thereof
INVENTOR(S): Pereira, H. Anne
PATENT ASSIGNEE(S): The Board of Regents of the University of Oklahoma, USA
SOURCE: U.S., 40 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6107460	A	20000822	US 1999-258934	19990301 <--
US 6514701	B1	20030204	US 2000-619283	20000719 <--
US 20040048792	A1	20040311	US 2002-328125	20021220 <--
US 6730659	B2	20040504		

PRIORITY APPLN. INFO.: US 1999-258934 A3 19990301 <--
US 2000-619283 A3 20000719 <--
OTHER SOURCE(S): MARPAT 133:187935
IT **151679-59-3** **288855-83-4** **288856-01-9**
288856-02-0 **288856-03-1** **288856-10-0**
288856-11-1 **288856-12-2** **288856-14-4**
288856-15-5 **288856-16-6**
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); PRP (Properties); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(antibacterial CAP37 peptides and therapeutic use thereof)
RN 151679-59-3 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B





PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288855-83-4 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-histidyl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA AHCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



RN 288856-01-9 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCAGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-02-0 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGAA LIHARFVMTA ASCFQ

Absolute stereochemistry.



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-03-1 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinyl-L-alanyl-L-alanyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCAAA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-10-0 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-threonyl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ATCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



PAGE 2-D

RN 288856-11-1 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-leucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFLMTA ASCFQ

Absolute stereochemistry.




HS
R
N
H
O
H
N
S
O
Ph
N
H
S
CO2H
NH2
O


NH


NH
(CH2)3
N
H
S
HN
O
N
N
H
S
N
H
O
S
H
S
Et
Me
i-Bu
H
N
O
S
N
H
O
S
H
N
Me

PAGE 2-B



PAGE 2-C



RN 288856-12-2 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-isoleucyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFIMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 2-A



PAGE 2-B



PAGE 2-C



RN 288856-14-4 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-

tyrosyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHYCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 2-A





SMe

RN 288856-15-5 CAPLUS
CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-tyrosyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARYVMTA ASCFQ

Absolute stereochemistry.





PAGE 1-C



PAGE 2-A







PAGE 2-B





RN 288856-16-6 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-tyrosyl- (9CI) (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCYQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B



PAGE 1-C



PAGE 1-D



REFERENCE COUNT: 36 THERE ARE 36 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L19 ANSWER 9 OF 20 CAPLUS COPYRIGHT 2008 ACS on STN
ACCESSION NUMBER: 2000:291095 CAPLUS <<LOGINID::20081208>>
DOCUMENT NUMBER: 132:329919
TITLE: Modified peptides containing an antibody Fc domain as therapeutic agents
INVENTOR(S): Feige, Ulrich; Liu, Chuan-fa; Cheetham, Janet; Boone, Thomas Charles
PATENT ASSIGNEE(S): Amgen Inc., USA
SOURCE: PCT Int. Appl., 608 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000024782	A2	20000504	WO 1999-US25044	19991025 <--
WO 2000024782	A3	20020606		

W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW

RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

US 6660843	B1	20031209	US 1999-428082	19991022	<--
CA 2347131	A1	20000504	CA 1999-2347131	19991025	<--
EP 1144454	A2	20011017	EP 1999-971003	19991025	<--
EP 1144454	A3	20020911			
EP 1144454	B1	20071212			

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, AL, MK

CN 1331701	A	20020116	CN 1999-814727	19991025	<--
CN 1310948	C	20070418			
BR 9914708	A	20020716	BR 1999-14708	19991025	<--
HU 2002003506	A2	20030228	HU 2002-3506	19991025	<--
JP 2003512011	T	20030402	JP 2000-578351	19991025	<--
AU 767725	B2	20031120	AU 2000-12322	19991025	<--
NZ 510888	A	20040130	NZ 1999-510888	19991025	<--
NZ 528882	A	20050624	NZ 1999-528882	19991025	<--
CN 1721447	A	20060118	CN 2005-10082591	19991025	<--
CN 1746189	A	20060315	CN 2005-10083696	19991025	<--
CN 100384880	C	20080430			
CN 1746190	A	20060315	CN 2005-10083697	19991025	<--
CN 1781945	A	20060607	CN 2005-10081495	19991025	<--
CN 100384879	C	20080430			
CN 1781946	A	20060607	CN 2005-10081496	19991025	<--
CN 1781947	A	20060607	CN 2005-10081497	19991025	<--
CN 1908014	A	20070207	CN 2005-10081952	19991025	<--
AT 380828	T	20071215	AT 1999-971003	19991025	<--
ES 2299278	T3	20080516	ES 1999-971003	19991025	<--
ZA 2001002753	A	20020611	ZA 2001-2753	20010404	<--
MX 2001PA03873	A	20031014	MX 2001-PA3873	20010417	<--
NO 2001001963	A	20010621	NO 2001-1963	20010420	<--
BG 105461	A	20030430	BG 2001-105461	20010424	<--
HK 1042097	A1	20080403	HK 2002-102701	20020410	<--
US 20040044188	A1	20040304	US 2003-609217	20030627	<--
US 7166707	B2	20070123			
US 20040053845	A1	20040318	US 2003-632388	20030731	<--
US 7189827	B2	20070313			
US 20040071712	A1	20040415	US 2003-645761	20030818	<--
US 20050123548	A1	20050609	US 2003-645784	20030818	<--
US 20040057953	A1	20040325	US 2003-651723	20030829	<--
US 7169905	B2	20070130			
US 20040087778	A1	20040506	US 2003-653048	20030829	<--
US 7186810	B2	20070306			
US 20040077022	A1	20040422	US 2003-666696	20030919	<--
AU 2004200687	A1	20040318	AU 2004-200687	20040220	<--
AU 2004200687	B2	20070510			
AU 2004200690	A1	20040318	AU 2004-200690	20040220	<--
AU 2004200690	B2	20070510			
AU 2004200691	A1	20040318	AU 2004-200691	20040220	<--
AU 2004200691	B2	20070329			

US 20060234307	A1	20061019	US 2006-472070		20060620 <--
JP 2007084555	A	20070405	JP 2006-288325		20061024 <--
JP 2007084556	A	20070405	JP 2006-288346		20061024 <--
JP 2007084557	A	20070405	JP 2006-288383		20061024 <--
JP 2007084558	A	20070405	JP 2006-288397		20061024 <--
JP 2007091746	A	20070412	JP 2006-288324		20061024 <--
JP 2007091747	A	20070412	JP 2006-288347		20061024 <--
JP 2007089586	A	20070412	JP 2006-288382		20061024 <--
JP 2007105044	A	20070426	JP 2006-288398		20061024 <--
US 20070049532	A1	20070301	US 2006-591002		20061031 <--
KR 2007050977	A	20070516	KR 2007-706958		20070327 <--
KR 2007050978	A	20070516	KR 2007-706961		20070327 <--
PRIORITY APPLN. INFO.:			US 1998-105371P	P	19981023 <--
			US 1999-428082	A	19991022 <--
			AU 2000-12322	A3	19991025 <--
			CN 1999-814727	A3	19991025 <--
			JP 2000-578351	A3	19991025 <--
			WO 1999-US25044	W	19991025 <--
			US 2000-563286	A1	20000503 <--
			KR 2001-704982	A3	20010420 <--
			US 2003-645761	A3	20030818
			US 2003-666696	A1	20030919
			AU 2004-200687	A	20040220

IT **151679-59-3D**, fusion protein with IgG1 Fc domain
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(CAP37 mimetic/LPS binding; modified peptides containing an antibody Fc domain as therapeutic agents)

RN 151679-59-3 CAPLUS

CN L-Glutamine, L-asparaginyl-L-glutaminylglycyl-L-arginyl-L-histidyl-L-phenylalanyl-L-cysteinylglycylglycyl-L-alanyl-L-leucyl-L-isoleucyl-L-histidyl-L-alanyl-L-arginyl-L-phenylalanyl-L-valyl-L-methionyl-L-threonyl-L-alanyl-L-alanyl-L-seryl-L-cysteinyl-L-phenylalanyl- (CA INDEX NAME)

SEQ 1 NQGRHFCGGA LIHARFVMTA ASCFQ

Absolute stereochemistry.

PAGE 1-A



PAGE 1-B